Shares of LifeStance Health Group, Inc. (LFST) surged over 5% in pre-market trading on Thursday after the outpatient mental healthcare provider reported better-than-expected third quarter 2024 results and raised its full-year guidance.
For the three months ended September 30, LifeStance posted a revenue of $312.7 million, up 19% year-over-year and beating consensus estimates of $302.6 million. The company's adjusted EBITDA more than doubled to $30.7 million, significantly exceeding analyst expectations of $18.2 million.
LifeStance's CEO Ken Burdick expressed satisfaction over the quarterly performance, stating, "We are pleased with the performance thus far in 2024 and, as we look to 2025, will continue striving to meet our commitments as we have done for the past eight consecutive quarters."
Encouraged by the strong results, the company raised its full-year 2024 guidance. LifeStance now expects total revenue in the range of $1.228 billion to $1.248 billion, up from its previous estimates. Additionally, the company raised its outlook for Center Margin to $382 million to $398 million, and Adjusted EBITDA to $105 million to $115 million. LifeStance also reiterated its expectations for positive Free Cash Flow for the full year.
Comments